Pharmacists and Advocacy for Patients in Pain | TWIRx
- 1h 9m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode explores the intersection of pain patient advocacy and community pharmacy practice through a conversation between the host, pharmacist Shane Jerominski, and Doctor Patient Forum leaders Claudia and Bev. The guests discuss how chronic pain patients face severe abandonment, forced tapers, and obstacles from prescription monitoring programs, while expressing concern over younger pharmacists mocking pain patients on social media. The host and guests debate the tone and rhetoric of opioid advocacy, including slogans like making Oxycontin great again, while agreeing that corporate metrics, understaffing, and legal pressure from the DEA and distributors put immense stress on both patients and pharmacists. Ultimately, the discussion shifts toward finding common ground, reforming workplace conditions through unionization, and uniting pharmacists and patients to push for regulatory oversight.
- Patients who have been on long-term opioid therapy face severe health harms when forced into rapid tapers or abrupt cutoffs. 16:19
- Pharmacists often operate under intense defensive pressure and corporate limits that restrict their ability to properly care for patients in pain. 37:42
- Unionization efforts like the Pharmacy Guild aim to improve staffing levels and give pharmacists more time for individualized patient care. 59:07
Highlights
- 1:59
The Origin of Patient Advocacystory
Bev Scheckman shares how her personal experience of being denied pain medication in the hospital for kidney stones led her to co-found the Doctor Patient Forum to fight for pain patients.
- 8:46
The Reality of Patient Abandonmentinsight
Claudia and Bev explain that their fierce advocacy stems from daily messages sent by desperate pain patients and individuals dealing with suicidal ideation due to a lack of proper care.
- 17:44
Double Standards in Drug Advocacydebate
Bev Scheckman highlights a double standard where pharmacy organizations fight against red flags for Suboxone and cash-only pay, but leave pain patients to fight opioid restrictions alone.
- 36:25
The Danger of Defensive Pharmacyinsight
Shane Jerominski explains how young pharmacists burdened by student debt and heavy workloads often err on the side of caution and turn away patients in need.
- 58:09
Unionizing for Better Carestrategy
Shane Jerominski details how the Pharmacy Guild is organizing stores across multiple states to improve working conditions and allow pharmacists to spend adequate time with patients.
- 1:03:31
Challenging Data Analytics Programsstrategy
Bev Scheckman discusses a citizen petition submitted to the FDA regarding data analytics programs like NarxCare, asking for transparency and regulation of medical device software.
About this episode
Pharmacists and Advocacy for Patients in Pain Friday, August 21, 2026 What happens when patients living with chronic pain, their advocates, and the pharmacists responsible for dispensing opioid medications view the same healthcare system from very different perspectives? This special episode of This Week in Pharmacy brings together the Doctor Patient Forum’s founders, Claudia A. Merandi and Bev C. Schechtman, with pharmacist and nationally recognized pharmacy advocate Dr. Shane Jerominski, PharmD—better known as “The Accidental Pharmacist.” The discussion follows a wave of social-media debate surrounding Claudia’s use of the term “Harmacists,” which prompted responses from hundreds of pharmacists who felt the label misrepresented their professional responsibilities and the legal restrictions under which they practice. Rather than allow that controversy to deepen the divide, TWIRx created an opportunity for direct, respectful conversation. The purpose of this episode is to help pain-patient advocates better understand the limits pharmacists face when dispensing opioids—and to identify opportunities for pharmacists and patient organizations to advocate together for safe, compassionate and uninterrupted pain care. Five Legal and Supply-Chain Realities Affecting Opioid Dispensing Pharmacists have a federal “corresponding responsibility.”Under 21 CFR §1306.04, a controlled-substance prescription must be issued for a legitimate medical purpose. Pharmacists share legal responsibility with prescribers for determining whether a prescription is valid. Knowingly filling an illegitimate prescription may expose the pharmacist to federal penalties and professional discipline. Review the federal regulation. Schedule II prescriptions must satisfy strict requirements. Federal law generally requires a valid written or compliant electronic prescription before a Schedule II opioid may be dispensed. Emergency oral prescriptions are permitted only under limited conditions and require prescriber follow-up documentation. Schedule II opioid prescriptions cannot be refilled. Under federal law, every additional dispensing generally requires a new prescription. Partial fills are allowed only under specific circumstances, documentation requirements and time limits. Pharmacists cannot simply extend or refill opioid therapy when a patient or prescriber requests it. State laws add another layer of requirements. Depending on the state, pharmacists may have to verify prescriber authority, review prescription-monitoring information, validate electronic or security-form requirements, confirm identification, document partial fills, or comply with state-specific dispensing limitations. For example, California requires controlled-substance prescriptions to meet defined security and validity standards. California Board of Pharmacy guidance. Wholesaler monitoring can restrict a pharmacy’s opioid supply. DEA-registered distributors must identify and report suspicious controlled-substance orders under 21 CFR §1301.74. National wholesalers therefore operate monitoring programs that may delay, limit or suspend shipments based on ordering patterns, geography, drug mix and internal thresholds. These controls are imposed upstream and can leave a pharmacy unable to obtain medication—even when the pharmacist believes a prescription is clinically and legally appropriate. Review the federal distributor requirements. These examples are not exhaustive. Pharmacists must navigate overlapping federal law, DEA requirements, state pharmacy and controlled-substance laws, prescription-monitoring systems, employer policies, payer rules, wholesaler restrictions and professional standards. Requirements also vary by state and by the circumstances surrounding an individual prescription. The Central Question How can pain-patient advocates and pharmacists move beyond blame and work together to address the policies, supply restrictions, staffing conditions and regulatory pressures th
Transcript
12,633 words · 4 speakers
Topics
- Pain Management
- Pharmacy Practice
- Patient Advocacy
- Opioid Crisis
- Healthcare Reform
- Labor Unions
Page updated · transcript and summary are machine-generated